A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin
The primary purpose of this study is to evaluate clinical and serologic outcomes after the discontinuation of liatermin therapy as assessed by development of new clinical conditions beyond those expected in patients with advancing Parkinson's disease. In addition, the development or resolution of anti-r-metHuGDNF binding and neutralizing antibodies will be monitored.
|Study Design:||Time Perspective: Prospective|
|Official Title:||A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin|
- Adverse Events [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
Biospecimen Retention: None Retained
|Study Start Date:||June 2005|
|Study Completion Date:||September 2007|
|Primary Completion Date:||November 2006 (Final data collection date for primary outcome measure)|
Subjects previously administered GDNF and have discontinued the drug.
Drug: Safety observation
Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00148369